Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

Background: Epigenetic changes may contribute importantly to cognitive decline in late life including Alzheimer’s disease (AD) and vascular dementia (VaD). Bromodomain and extra-terminal (BET) proteins are epigenetic “readers” that may distort normal gene expression and contribute to chronic disorde...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Alzheimer's disease 2021-01, Vol.83 (4), p.1703-1715
Hauptverfasser:	Cummings, Jeffrey, Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Halliday, Chris, Toth, Peter P., Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Lebioda, Kenneth, Ginsberg, Henry N., Winblad, Bengt, Zetterberg, Henrik, Ray, Kausik K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer's disease alzheimers-disease apabetalone assessment moca BET inhibitor Bet protein biomarkers blood-brain-barrier bromodomain Cardiovascular diseases Cardiovascular Diseases - complications clinical trial Cognition Cognition & reasoning Cognitive ability Cognitive Dysfunction - prevention & control Dementia Dementia disorders Disorders Epigenesis, Genetic Epigenetics Female Gene expression Health risks Humans inflammation Inhibitors Male Mental Status and Dementia Tests - statistics & numerical data Middle Aged montreal cognitive assessment Neurodegenerative diseases Neurosciences Neurosciences & Neurology Neurovetenskaper Patients Placebos Proteins Quinazolinones - administration & dosage Randomization risk Vascular dementia
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!